FDA-cleared profile

Koios DS

Koios Medical, Inc. · Ultrasound · FDA-cleared (510(k))

Authorized purpose: Koios DS is an artificial intelligence (AI)/machine learning (ML)-based computer-aided diagnosis (CADx) software device intended for use as an adjunct to diagnostic ultrasound examinations of lesions or nodules suspicious for breast or thyroid cancer. Koios DS allows the user to select or confirm regions of interest (ROIs) within an image representing a single lesion or nodule to be analyzed. The software then automatically characterizes the selected image data to generate an AI/ML-derived cancer risk assessment and selects applicable lexicon-based descriptors designed to improve overall diagnostic accuracy as well as reduce interpreting physician variability. Koios DS may also be used as an image viewer of multi-modality digital images, including ultrasound and mammography. The software includes tools that allow users to adjust, measure and document images, and output into a structured report. Koios DS software is designed to assist trained interpreting physicians in analyzing the breast ultrasound images of adult (>= 22 years) female patients with soft tissue breast lesions and/or thyroid ultrasounds of all adult (>= 22 years) patients with thyroid nodules suspicious for cancer. When utilized by an interpreting physician who has completed the prescribed training, this device provides information that may be useful in recommending appropriate clinical management. Limitations: Patient management decisions should not be made solely on the results of the Koios DS analysis. Koios DS software is not to be used for the evaluation of normal tissue, on sites of post-surgical excision, or images with doppler, elastography, or other overlays present in them. Koios DS software is not intended for use on portable handheld devices (e.g. smartphones or tablets) or as a primary diagnostic viewer of mammography images. The software does not predict the presence of the thyroid nodule margin descriptor, extra-thyroidal extension. In the event that this condition is present, the user may select this category manually from the margin descriptor list.

Clinical role
Adjunct CADx: user selects or confirms ROIs of a breast lesion or thyroid nodule on ultrasound; software returns an AI/ML cancer risk assessment and lexicon-based descriptors as concurrent read and report input, addable to the DICOM series or draft report.
Images and patients
Ultrasound · Breast
Key limitation
Keep in mind: Patient management decisions should not be made solely on the results of the Koios DS analysis. Koios DS is not for normal tissue, post-surgical excision sites, or images with doppler, elastography, or other overlays; it is not intended for portable handheld devices or as a primary diagnostic viewer of mammography images; and it does not predict the thyroid nodule margin descriptor extra-thyroidal extension.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Koios DS is an artificial intelligence (AI)/machine learning (ML)-based computer-aided diagnosis (CADx) software device intended for use as an adjunct to diagnostic ultrasound examinations of lesions or nodules suspicious for breast or thyroid cancer. Koios DS allows the user to select or confirm regions of interest (ROIs) within an image representing a single lesion or nodule to be analyzed. The software then automatically characterizes the selected image data to generate an AI/ML-derived cancer risk assessment and selects applicable lexicon-based descriptors designed to improve overall diagnostic accuracy as well as reduce interpreting physician variability. Koios DS may also be used as an image viewer of multi-modality digital images, including ultrasound and mammography. The software includes tools that allow users to adjust, measure and document images, and output into a structured report. Koios DS software is designed to assist trained interpreting physicians in analyzing the breast ultrasound images of adult (>= 22 years) female patients with soft tissue breast lesions and/or thyroid ultrasounds of all adult (>= 22 years) patients with thyroid nodules suspicious for cancer. When utilized by an interpreting physician who has completed the prescribed training, this device provides information that may be useful in recommending appropriate clinical management. Limitations: Patient management decisions should not be made solely on the results of the Koios DS analysis. Koios DS software is not to be used for the evaluation of normal tissue, on sites of post-surgical excision, or images with doppler, elastography, or other overlays present in them. Koios DS software is not intended for use on portable handheld devices (e.g. smartphones or tablets) or as a primary diagnostic viewer of mammography images. The software does not predict the presence of the thyroid nodule margin descriptor, extra-thyroidal extension. In the event that this condition is present, the user may select this category manually from the margin descriptor list.
  • Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Breast Input: Medical images provided in a DICOM format; selected breast or thyroid ultrasound images are processed after the user selects or confirms regions of interest.
  • Who uses it?Intended users: Physician
  • What does the software produce?Output: Koios DS Breast provides categorical and continuous outputs aligned to BI-RADS and U1-U5 with auto-classified shape and orientation. Koios DS Thyroid automatically classifies thyroid nodules with output aligned to TI-RADS or ATA, generates user-modifiable nodule descriptors, and provides a direct image-derived cancer risk assessment translated into an optional lexicon-specific modifier.
  • What is its most important limitation?Key limitation: Patient management decisions should not be made solely on the results of the Koios DS analysis. Koios DS is not for normal tissue, post-surgical excision sites, or images with doppler, elastography, or other overlays; it is not intended for portable handheld devices or as a primary diagnostic viewer of mammography images; and it does not predict the thyroid nodule margin descriptor extra-thyroidal extension.

Clinical takeaway. Clinical role: Koios DS is an artificial intelligence (AI)/machine learning (ML)-based computer-aided diagnosis (CADx) software device intended for use as an adjunct to diagnostic ultrasound examinations of lesions or nodules suspicious for breast or thyroid cancer. Koios DS allows the user to select or confirm regions of interest (ROIs) within an image representing a single lesion or nodule to be analyzed. The software then automatically characterizes the selected image data to generate an AI/ML-derived cancer risk assessment and selects applicable lexicon-based descriptors designed to improve overall diagnostic accuracy as well as reduce interpreting physician variability. Koios DS may also be used as an image viewer of multi-modality digital images, including ultrasound and mammography. The software includes tools that allow users to adjust, measure and document images, and output into a structured report. Koios DS software is designed to assist trained interpreting physicians in analyzing the breast ultrasound images of adult (>= 22 years) female patients with soft tissue breast lesions and/or thyroid ultrasounds of all adult (>= 22 years) patients with thyroid nodules suspicious for cancer. When utilized by an interpreting physician who has completed the prescribed training, this device provides information that may be useful in recommending appropriate clinical management. Limitations: Patient management decisions should not be made solely on the results of the Koios DS analysis. Koios DS software is not to be used for the evaluation of normal tissue, on sites of post-surgical excision, or images with doppler, elastography, or other overlays present in them. Koios DS software is not intended for use on portable handheld devices (e.g. smartphones or tablets) or as a primary diagnostic viewer of mammography images. The software does not predict the presence of the thyroid nodule margin descriptor, extra-thyroidal extension. In the event that this condition is present, the user may select this category manually from the margin descriptor list.

Evidence takeaway. Evidence from the reviewed source record: The breast and thyroid engine validation sets are composed of 900 lesions from 900 different patients and 650 lesions from 650 different patients, respectively, and each was set aside from the systems' training data. The number of interpreting physicians utilized in both studies was 15 readers.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Koios DS is an artificial intelligence (AI)/machine learning (ML)-based computer-aided diagnosis (CADx) software device intended for use as an adjunct to diagnostic ultrasound examinations of lesions or nodules suspicious for breast or thyroid cancer. Koios DS allows the user to select or confirm regions of interest (ROIs) within an image representing a single lesion or nodule to be analyzed. The software then automatically characterizes the selected image data to generate an AI/ML-derived cancer risk assessment and selects applicable lexicon-based descriptors designed to improve overall diagnostic accuracy as well as reduce interpreting physician variability. Koios DS may also be used as an image viewer of multi-modality digital images, including ultrasound and mammography. The software includes tools that allow users to adjust, measure and document images, and output into a structured report. Koios DS software is designed to assist trained interpreting physicians in analyzing the breast ultrasound images of adult (>= 22 years) female patients with soft tissue breast lesions and/or thyroid ultrasounds of all adult (>= 22 years) patients with thyroid nodules suspicious for cancer. When utilized by an interpreting physician who has completed the prescribed training, this device provides information that may be useful in recommending appropriate clinical management. Limitations: Patient management decisions should not be made solely on the results of the Koios DS analysis. Koios DS software is not to be used for the evaluation of normal tissue, on sites of post-surgical excision, or images with doppler, elastography, or other overlays present in them. Koios DS software is not intended for use on portable handheld devices (e.g. smartphones or tablets) or as a primary diagnostic viewer of mammography images. The software does not predict the presence of the thyroid nodule margin descriptor, extra-thyroidal extension. In the event that this condition is present, the user may select this category manually from the margin descriptor list.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Adjunct CADx: user selects or confirms ROIs of a breast lesion or thyroid nodule on ultrasound; software returns an AI/ML cancer risk assessment and lexicon-based descriptors as concurrent read and report input, addable to the DICOM series or draft report.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "computer-aided diagnosis (CADx) software device intended for use as an adjunct to diagnostic ultrasound examinations of lesions or nodules suspicious for breast or thyroid cancer." … "allows the user to select or confirm regions of interest (ROIs) within an image representing a single lesion or nodule to be analyzed. The software then automatically characterizes the selected image data to generate an AI/ML-derived cancer risk assessment and selects applicable lexicon-based descriptors". Read from the exact FDA decision document on 2026-11-14.

Required input
Medical images provided in a DICOM format; selected breast or thyroid ultrasound images are processed after the user selects or confirms regions of interest.
  • Exact FDA submission
  • Checked 2026-09-19

The packet states DICOM medical-image input and user-selected or confirmed regions for breast or thyroid ultrasound; the current value is incomplete.

Output and clinician action
Koios DS Breast provides categorical and continuous outputs aligned to BI-RADS and U1-U5 with auto-classified shape and orientation. Koios DS Thyroid automatically classifies thyroid nodules with output aligned to TI-RADS or ATA, generates user-modifiable nodule descriptors, and provides a direct image-derived cancer risk assessment translated into an optional lexicon-specific modifier.
  • Exact FDA submission
  • Checked 2026-09-19

The exact packet describes both breast and thyroid outputs; the current value covers only the thyroid output and is sourced from a non-FDA model card.

Care setting
Adult
  • Exact FDA submission
  • Checked 2026-09-01

Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.

Intended users
Physician
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Limitations
Patient management decisions should not be made solely on the results of the Koios DS analysis. Koios DS is not for normal tissue, post-surgical excision sites, or images with doppler, elastography, or other overlays; it is not intended for portable handheld devices or as a primary diagnostic viewer of mammography images; and it does not predict the thyroid nodule margin descriptor extra-thyroidal extension.
  • Exact FDA submission
  • Checked 2026-09-19

The current limitations value only says 'Scanner manufacturers: All'; this replacement uses the packet's explicit labeled limitations.

Evidence summary
The breast and thyroid engine validation sets are composed of 900 lesions from 900 different patients and 650 lesions from 650 different patients, respectively, and each was set aside from the systems' training data. The number of interpreting physicians utilized in both studies was 15 readers.
  • Exact FDA submission
  • Checked 2026-09-19

The exact packet supports these validation-set and reader facts; the current reader-study metadata includes an unsupported null reference-standard field and does not state the packet's validation description.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The breast and thyroid engine validation sets are composed of 900 lesions from 900 different patients and 650 lesions from 650 different patients, respectively, and each was set aside from the systems' training data. The number of interpreting physicians utilized in both studies was 15 readers.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

The exact packet supports these validation-set and reader facts; the current reader-study metadata includes an unsupported null reference-standard field and does not state the packet's validation description.

Reported sensitivity
5%; 92.9%; 0.511%
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-13

Values reported in the exact-submission materials. Consult the linked source for endpoint, threshold, population, and confidence interval before comparison.

Reported specificity
24%; 18.741%
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-13

Values reported in the exact-submission materials. Consult the linked source for endpoint, threshold, population, and confidence interval before comparison.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Koios DS- Thyroid regulatory performance study summary

  • DesignReader Study
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K212616
  • IndependenceIndependence not established

K212616

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K212616. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Medical images provided in a DICOM format; selected breast or thyroid ultrasound images are processed after the user selects or confirms regions of interest.

    Scope: Exact FDA submission. The packet states DICOM medical-image input and user-selected or confirmed regions for breast or thyroid ultrasound; the current value is incomplete.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K212616: Koios DS

  2. Routing

    Source context, not route validation: The exact FDA package describes Koios DS querying and accepting DICOM compliant files from compliant devices, and saving or transferring results by in-transit transmission, saving to PACS, or exporting to third-party reporting software. Interface versions and local compatibility require confirmation.

    Scope: Exact FDA submission. Packet wording: "It is a platform-agnostic web application that queries and accepts DICOM compliant digital medical files from any compliant device subject to the specified DICOM Conformance Statement for Koios DS." … "Koios DS results can be saved or transferred in three separate ways: in-transit transmission, saving to Picture Archiving and Communication System (PACS), and exporting results to third-party reporting software.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-11-14 · FDA K212616: Koios DS

  3. AI processing

    Source context, not route validation: The exact FDA package describes Koios DS as an ASP.NET web application deployed to a Microsoft IIS web server inside a Windows operating system environment and accessed by a user through a compatible client. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "Koios DS is an ASP.NET web application deployed to a Microsoft IIS web server inside a Windows operating system environment accessed by a user through a compatible client.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K212616: Koios DS

  4. Returned objects

    Source context, not route validation: Koios DS Breast provides categorical and continuous outputs aligned to BI-RADS and U1-U5 with auto-classified shape and orientation. Koios DS Thyroid automatically classifies thyroid nodules with output aligned to TI-RADS or ATA, generates user-modifiable nodule descriptors, and provides a direct image-derived cancer risk assessment translated into an optional lexicon-specific modifier.

    Scope: Exact FDA submission. The exact packet describes both breast and thyroid outputs; the current value covers only the thyroid output and is sourced from a non-FDA model card.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K212616: Koios DS

  5. Viewer/worklist/report

    Unresolved route: Koios DS Breast provides categorical and continuous outputs aligned to BI-RADS and U1-U5 with auto-classified shape and orientation. Koios DS Thyroid automatically classifies thyroid nodules with output aligned to TI-RADS or ATA, generates user-modifiable nodule descriptors, and provides a direct image-derived cancer risk assessment translated into an optional lexicon-specific modifier.

    Scope: Exact FDA submission. The exact packet describes both breast and thyroid outputs; the current value covers only the thyroid output and is sourced from a non-FDA model card.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K212616: Koios DS

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes Koios DS as an ASP.NET web application deployed to a Microsoft IIS web server inside a Windows operating system environment and accessed by a user through a compatible client. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Koios DS is an ASP.NET web application deployed to a Microsoft IIS web server inside a Windows operating system environment accessed by a user through a compatible client.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The exact FDA package describes Koios DS querying and accepting DICOM compliant files from compliant devices, and saving or transferring results by in-transit transmission, saving to PACS, or exporting to third-party reporting software. Interface versions and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "It is a platform-agnostic web application that queries and accepts DICOM compliant digital medical files from any compliant device subject to the specified DICOM Conformance Statement for Koios DS." … "Koios DS results can be saved or transferred in three separate ways: in-transit transmission, saving to Picture Archiving and Communication System (PACS), and exporting results to third-party reporting software.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Supported acquisition environment

Scanner manufacturers: All

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for Koios DS; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K212616
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Ultrasound
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Anatomy
Breast
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

The exact indications cover lesions or nodules suspicious for breast or thyroid cancer; the current anatomy value retains only breast. Controlled directory display reconciled from exact FDA wording: Breast and thyroid. -> Breast.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2021-12-16
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
28Fields reviewed
10Source classes checked
14Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 14 PubMed and 0 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 14 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K212616 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-08 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K212616: Koios DS

    U.S. Food and Drug Administration - Published 2021-12-16 - Accessed 2026-09-19

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, purpose, intendedUsers, input, output, limitations, evidenceSummary, deployment, integration

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Koios DS- Thyroid model card (K212616)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, evidenceSummary, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K212616

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

Research history

  1. K212616 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K242130

Koios DS

Koios Medical, Inc.

Authorized purpose: Koios Decision Support (DS) is an artificial intelligence (AI)/machine learning (ML)-based computer-aided diagnosis (CADx) software device intended for use as an adjunct to diagnostic ultrasound examinations of lesions or nodules suspicious for breast or thyroid cancer. Koios DS allows the user to select or confirm regions of interest (ROIs) within an image representing a single lesion or nodule to be analyzed. The software then automatically characterizes the selected image data to generate an AI/MLderived cancer risk assessment and selects applicable lexicon-based descriptors designed to improve overall diagnostic accuracy as well as reduce interpreting physician variability. Koios DS software may also be used as an image viewer of multi-modality digital images, including ultrasound and mammography. The software includes tools that allow users to adjust, measure and document images, and output into a structured report. Koios DS software is designed to assist trained interpreting physicians in analyzing the breast ultrasound images of adult (>= 22 years) female patients with soft tissue breast lesions and/or thyroid ultrasounds of all adult (>= 22 years) patients with thyroid nodules suspicious for cancer. When utilized by an interpreting physician who has completed the prescribed training, this device provides information that may be useful in recommending appropriate clinical management.

Modality
Ultrasound
Anatomy
Breast
Decision
2024-11-15
FDA-cleared K161959

ClearView cCAD

ClearView Diagnostics Inc.

ClearView cCAD is a software application designed to assist skilled physicians in analyzing breast ultrasound images. It automatically classifies shape and orientation characteristics of user-selected regions of interest. this device uses multivariate pattern recognition methods to perform characterization and classification of images.

Modality
Ultrasound
Anatomy
Breast
Decision
2016-12-28
FDA-cleared K251368

FETOLY

Diagnoly

Authorized purpose: FETOLY analyzes fetal ultrasound images and sequences to detect labeled fetal brain and heart views, assess image completeness or quality, and provide fetal biometric measurements during the second and third trimesters.

Modality
Ultrasound
Anatomy
Fetal heart and fetal brain
Decision
2025-09-12
FDA-cleared K242594

DEEPECHO

DeepEcho

Authorized purpose: Detect standard fetal biometry views and assist fetal biometry measurements during prenatal ultrasound acquisition and interpretation.

Modality
Ultrasound
Anatomy
Fetal biometry views and structures: cephalic/head, abdomen, and femur
Decision
2025-05-23

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history